Clinical Trial Update: Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a recombinant anti-HER2 monoclonal antibody in early phases for HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• recombinant anti-HER2 humanized monoclonal antibody for injection

Snippet

Sponsor: Genor Biopharma Co., Ltd. | Conditions: HER2-positive Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN